⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TVRD News
Tvardi Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
TVRD
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
globenewswire.com
TVRD
Form 8-K
sec.gov
TVRD
Form 8-K
sec.gov
TVRD
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
globenewswire.com
TVRD
Form 8-K
sec.gov
TVRD
Tvardi Therapeutics to Participate in Upcoming Investor Events
globenewswire.com
TVRD
Tevard Biosciences Presents Preclinical Data Showing Complete Dystrophin Restoration and Robust Titin Rescue with Suppressor tRNA Therapy at ASGCT 2026 Ready to Announce with Confidence?
newsfilecorp.com
TVRD
Form 8-K
sec.gov
TVRD
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
globenewswire.com
TVRD